Leah R. Mursaleen

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.

Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: January 29, 2026

Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.

Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.

Journal: Journal of Parkinson's disease

Published: April 05, 2024

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.

Journal: Journal of Parkinson's disease

Published: June 11, 2023

Curcumin and N-Acetylcysteine Nanocarriers Alone or Combined with Deferoxamine Target the Mitochondria and Protect against Neurotoxicity and Oxidative Stress in a Co-Culture Model of Parkinson's Disease.

Curcumin and N-Acetylcysteine Nanocarriers Alone or Combined with Deferoxamine Target the Mitochondria and Protect against Neurotoxicity and Oxidative Stress in a Co-Culture Model of Parkinson's Disease.

Journal: Antioxidants (Basel, Switzerland)

Published: December 07, 2022

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.

Journal: Journal of Parkinson's disease

Published: May 09, 2022

Waiting for PARIS-A Biological Target in Search of a Drug.

Waiting for PARIS-A Biological Target in Search of a Drug.

Journal: Journal of Parkinson's disease

Published: November 08, 2021

Micellar Nanocarriers of Hydroxytyrosol Are Protective against Parkinson's Related Oxidative Stress in an In Vitro hCMEC/D3-SH-SY5Y Co-Culture System.

Micellar Nanocarriers of Hydroxytyrosol Are Protective against Parkinson's Related Oxidative Stress in an In Vitro hCMEC/D3-SH-SY5Y Co-Culture System.

Journal: Antioxidants (Basel, Switzerland)

Published: May 05, 2021

N-Acetylcysteine Nanocarriers Protect against Oxidative Stress in a Cellular Model of Parkinson's Disease.

N-Acetylcysteine Nanocarriers Protect against Oxidative Stress in a Cellular Model of Parkinson's Disease.

Journal: Antioxidants (Basel, Switzerland)

Published: June 19, 2020

Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases Serum BDNF Levels in Healthy Adults.

Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases Serum BDNF Levels in Healthy Adults.

Journal: Antioxidants (Basel, Switzerland)

Published: June 19, 2020

GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.

GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.

Journal: Journal of Parkinson's disease

Published: June 09, 2020

Deferoxamine and Curcumin Loaded Nanocarriers Protect Against Rotenone-Induced Neurotoxicity.

Deferoxamine and Curcumin Loaded Nanocarriers Protect Against Rotenone-Induced Neurotoxicity.

Journal: Journal of Parkinson's disease

Published: December 24, 2019

The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison.

The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: July 20, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026